PATIENT PROFILES

Take a closer look at the types of patients who may benefit from NEMLUVIO

MEET WENDY

Can't sleep well due to continuous itching

MEET EMILY

Anxious her scratching and flaking is negatively impacting family time

MEET MATTHEW

Constant scratching is affecting his ability to concentrate at school

Actor portrayals.

Wendy and her spouse can't sleep well due to her continuous itching

Age: 32 years

Diagnosis: Atopic dermatitis

BSA: 20%

Signs and Symptoms:

  • Itchiness and frequent flares
  • Dry, flaky skin
  • Scratch marks
  • Frequent flares that lead to avoidance of social activities
An image of an itch scale from 0 to 10, with a score of 9 showing on the scale. An image of an itch scale from 0 to 10, with a score of 9 showing on the scale. An image of an IGA scale from 0 to 4, with a score of 3 showing on the scale. An image of an IGA scale from 0 to 4, with a score of 3 showing on the scale.

Emily worries her scratching and flaking makes family time awkward

Age: 41 years

Diagnosis: Atopic dermatitis

BSA: 50%

Signs and Symptoms:

  • Continuous scratching that’s making skin worse
  • Rough, scaly, dry skin
  • Thickened patches
  • Missed work due to symptoms
An image of an itch scale from 0 to 10, with a score of 6 showing on the scale. An image of an itch scale from 0 to 10, with a score of 6 showing on the scale. An image of an IGA scale from 0 to 4, with a score of 4 showing on the scale. An image of an IGA scale from 0 to 4, with a score of 4 showing on the scale.

Matthew is unable to concentrate at school due to his constant scratching

Age: 16 years

Diagnosis: Atopic dermatitis

BSA: 30%

Signs and Symptoms:

  • Itchiness and frequent flares
  • Dry, flaky skin
  • Has difficulty sleeping
  • Feels anxious
An image of an itch scale from 0 to 10, with a score of 8 showing on the scale. An image of an itch scale from 0 to 10, with a score of 8 showing on the scale. An image of an IGA scale from 0 to 4, with a score of 3 showing on the scale. An image of an IGA scale from 0 to 4, with a score of 3 showing on the scale.

Lasting Skin Healing1

Discover how NEMLUVIO helped most patients with AD achieve lasting skin clearance1

SEE THE DIFFERENCE 

Frequently Asked Questions

Questions about NEMLUVIO? 
We have the answers

LEARN MORE 

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.